2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
Why now
Thesis: First-in-human data hints at easier CAR-T delivery
Catalyst to watch: Trial expansion and peer review
Main risk: Very early data, small patient numbers
Why it matters
In vivo CAR-T without lymphodepletion could lower treatment burden, but the issuer is outside the allowed ticker set.
Details
— Late-breaking oral presentation of first-in-human data (LBA-11) showed that a single intravenous infusion of IASO206 generated functional BCMA CAR-T cells in vivo without lymphodepleting chemotherapy. The study demonstrated a 90% objective response rate and a 90% MRD negativity rate in...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-27 03:03 UTC